Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.

International journal of cancer - 1 Jun 2009

Stark Jennifer Rider, Li Haojie, Kraft Peter, Kurth Tobias, Giovannucci Edward L, Stampfer Meir J, Ma Jing, Mucci Lorelei A

Abstract excerpt

Interleukin-6 (IL-6) and C-reactive protein (CRP) are elevated in prostate cancer patients, but the role of prediagnostic levels of these inflammatory mediators on prostate cancer outcomes is unclear. We undertook a large, prospective case-control study to evaluate the relation between prediagnos...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Body Mass Index
Share to C-Reactive Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Case-Control Studies

Share to Double-Blind Method

Share to Interleukin-6

Share to Polymorphism, Single Nucleotide

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 19189403
DOI: 10.1002/ijc.24241
PMCID: PMC2667697

Genes

CRP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19189403-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.PMID 19189403Read ↗

C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older.Semantic proximity Read ↗

Interleukins-6 -174G/C (rs1800795) and -572C/G (rs1800796) polymorphisms and prostate cancer risk.Semantic proximity Read ↗

Role of interleukin-6 gene polymorphisms in the development of prostate cancer.Semantic proximity Read ↗

The interleukin-6 -174G/C polymorphism and prostate cancer risk: a systematic review and meta-analysis.Semantic proximity Read ↗

Interleukin-6 -572G/C polymorphism and prostate cancer susceptibility.Semantic proximity Read ↗

Interleukin-6 gene -174G>C and -636G>C promoter polymorphisms and prostate cancer risk.Semantic proximity Read ↗

The Role of Interleukin-6 Polymorphism (rs1800795) in Prostate Cancer Development and Progression.Semantic proximity Read ↗

Interleukin-6 promoter variants, prostate cancer risk, and survival.Semantic proximity Read ↗

-174G/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race.Semantic proximity Read ↗

Interleukin-6 polymorphism and prostate cancer risk in population of Eastern Croatia.Semantic proximity Read ↗

Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer.Semantic proximity Read ↗

Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.